Cambridge Advisors Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Cambridge Advisors reduced its stake in Becton Dickinson and Co by 1.56% during the most recent quarter end. The investment management company now holds a total of 3,165 shares of Becton Dickinson and Co which is valued at $552,387 after selling 50 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Becton Dickinson and Co makes up approximately 0.25% of Cambridge Advisors’s portfolio.

Other Hedge Funds, Including , Argus Investors’ Counsel reduced its stake in BDX by selling 2,300 shares or 7.4% in the most recent quarter. The Hedge Fund company now holds 28,790 shares of BDX which is valued at $5,024,719. Becton Dickinson and Co makes up approx 2.04% of Argus Investors’ Counsel’s portfolio.Checchi Capital Advisers boosted its stake in BDX in the latest quarter, The investment management firm added 14 additional shares and now holds a total of 1,786 shares of Becton Dickinson and Co which is valued at $310,175. Becton Dickinson and Co makes up approx 0.08% of Checchi Capital Advisers’s portfolio.Pennsylvania Trust Co boosted its stake in BDX in the latest quarter, The investment management firm added 310 additional shares and now holds a total of 4,488 shares of Becton Dickinson and Co which is valued at $788,901. Becton Dickinson and Co makes up approx 0.06% of Pennsylvania Trust Co’s portfolio.

Becton Dickinson and Co opened for trading at $175.65 and hit $176.98 on the upside on Friday, eventually ending the session at $176, with a gain of 0.02% or 0.04 points. The heightened volatility saw the trading volume jump to 7,75,782 shares. Company has a market cap of $37,348 M.

On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.

Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.